<DOC>
	<DOCNO>NCT02979366</DOCNO>
	<brief_summary>The CL1-64315-001 study phase I , international , multicentre , open-label , non-randomised , non-comparative study . This study design two part : one part dose escalation , one part dose expansion .</brief_summary>
	<brief_title>Phase I Study S64315 Administred Intravenously Patients With Acute Myeloid Leukaemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Male female age ≥ 18 year ; Patients cytologically confirm document de novo , secondary therapyrelated AML , exclude acute promyelocytic leukaemia ( APL , FrenchAmerican British M3 classification ) : relapse refractory disease without establish alternative therapy secondary MDS treat least hypomethylating agent &gt; 65 year previously treat AML candidate intensive chemotherapy candidate establish alternative chemotherapy Or Patients cytologically confirm document MDS ) , relapse refractory previous treatment line include least one hypomethylating agent ≥10 % bone marrow blast ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Circulating white blood cell &lt; 25.1000000000 /L ( without use hydroxycarbamide ) . Adequate renal function define : • Serum creatinine ≤ 1.5 x ULN ( upper normal limit ) calculate creatinine clearance ( determined MDRD ) &gt; 50 mL/min/1.73m2 . LDH &lt; 2 x ULN Adequate hepatic function define : AST ALT ≤ 3 x ULN Total bilirubin level ≤ 1.5 x ULN , except patient know Gilbert 's syndrome ( confirm UGT1A1 polymorphism analysis ) , exclude total bilirubin &gt; 3.0 x ULN direct bilirubin &gt; 1.5 x ULN Serum CK/CPK ≤2.5 x ULN . Unlikely cooperate study . Participant already enrol study receive least one S64315 infusion . Pregnancy , breastfeed possibility become pregnant study . Participation another interventional study require investigational treatment intake within 2 week least 5 halflives ( whichever longer ) prior first dose S64315 ( participation noninterventional registry epidemiological study allow ) . Presence ≥ CTCAE grade 2 toxicity ( except alopecia grade ) due prior cancer therapy , accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE , version 4.03 ) Known carrier HIV antibody Known history significant liver disease Uncontrolled hepatitis B C infection Known active chronic pancreatitis History myocardial infarction ( MI ) , angina pectoris , coronary artery bypass graft ( CABG ) within 6 month prior start study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>